JS111 capsules (AP-L1898)

DRUG2 trials

Sponsors

Suzhou Junjing BioSciences Co., Ltd., Huan Zhou

Conditions

NSCLCNSCLC Harboring EGFR Mutations

Phase 1

JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations

Active, not recruitingNCT06940401

Suzhou Junjing BioSciences Co., Ltd.NSCLC

Start: 2025-04-30End: 2028-09-30Updated: 2026-07-07

Unknown Phase

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

Not yet recruitingNCT07714304

Huan ZhouNSCLC Harboring EGFR Mutations

Start: 2026-07-13End: 2029-07-23Target: 20Updated: 2026-07-20